2024

  1. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. Stattin P, Fleming S, Lin X, Lefresne F, Brookman-May SD, Mundle SD, Pai H, Gifkins D, Robinson D, Styrke J, Garmo H. BJU Int. 2024 Apr. Sammafattning Fulltext
  2. Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial. Astrid E Persson EK, Hans Garmo, Gabriel Adrian, Pär Stattin, Anders Widmark, Per, Nilsson AG.  Abstract, ESTRO 2024. Länk till abstract
  3. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 – a case-control study. Ahlberg M, Garmo H, Stattin P, Gedeborg R, Edlund C, Holmberg L, Bill-Axelson A. Scand J Urol. 2024 Mar. Sammanfattning Fulltext
  4. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, Lissbrant IF, Stattin P, Bratt O.  Int J Cancer. 2024 Mar. Sammanfattning Fulltext
  5. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. Lundberg F, Robinson D, Bratt O, Fallara G, Lambe M, Johansson ALV. Acta Oncol. 2024 Mar. Sammanfattning Fulltext.
  6. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, Nagel G, Zitt E, Engeland A, Harlid S, Drake I, Stattin P, Stocks T.  Br J Cancer. 2024 Feb. Sammanfattning Fulltext
  7. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study. Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. PLoS One. 2024 Jan. Sammanfattning Fulltext
  8. Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study. Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, Kindblom J, Robinson D, Westerberg M, Stattin P, Carlsson SV. Eur Urol Oncol. 2024 Jan. Sammanfattning Fulltext